Table 3.
Comparison of blood lipid levels between two groups of patients before and after treatment
|
Parameter
|
Time
|
CM group (n = 107)
|
CSCT group (n = 104)
|
t
|
P value
|
| Tot-cholesterol (mg/dL) | Baseline | 177.23 ± 34.56 | 180.25 ± 32.56 | 0.653 | 0.515 |
| 6 months | 171.45 ± 32.69 | 162.41 ± 31.79 | 2.037 | 0.043 | |
| HDL (mg/dL) | Baseline | 45.26 ± 9.56 | 45.15 ± 9.89 | 0.079 | 0.937 |
| 6 months | 45.34 ± 8.66 | 47.69 ± 8.28 | 2.017 | 0.045 | |
| LDL (mg/dL) | Baseline | 101.49 ± 35.26 | 105.21 ± 35.46 | 0.764 | 0.446 |
| 6 months | 94.86 ± 27.64 | 86.74 ± 27.12 | 2.154 | 0.032 | |
| Triglycerides (mg/dL) | Baseline | 145.32 ± 35.64 | 142.89 ± 35.39 | 0.496 | 0.621 |
| 6 months | 135.21 ± 28.22 | 127.56 ± 25.26 | 2.072 | 0.040 |
HDL: High density lipoprotein; LDL: Low density lipoprotein; CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.